With its ability to significantly reduce ApoB‐containing lipoprotein levels and a safety profile similar to placebo, obicetrapib has the potential to be a new agent in the armamentarium for dyslipidemia management and ASCVD risk reduction. The gene discussed is APOB; the disease is atherosclerosis.